Melmon K L, Cline M J, Hughes T, Nies A S
J Clin Invest. 1968 Jun;47(6):1295-302. doi: 10.1172/JCI105821.
Bradykinin is a potent constrictor of the human umbilical artery and vein and the ductus arteriosus of the lamb in vitro at oxygen tensions above 40 mm Hg (comparable to those in the newborn infant). Bradykinin is also capable of producing remarkable dilatation of the pulmonary vasculature of the lamb. Theoretically, kinins are capable of effecting some of the rapid circulatory changes required of the neonate. The present study was undertaken to investigate the role of kinins as mediators of such changes. The concentration of bradykinin in the cord blood of 56 newborn infants at the time of birth was significantly higher than the blood level in adult subjects (12.8 +/- 4.3 ng/ml compared with 2.0 ng/ml or less). Cord arterial blood contained inactive kinin precursor (kininogen) and inactive kinin-releasing enzyme (kallikrein). Plasma kallikrein was activated, with subsequent kinin formation and kininogen depletion, by exposure to neonatal granulocytes or by a decrease in the temperature of cord blood from 37 to 27 degrees C. A comparable decrease in the temperature of umbilical arterial blood occurs at the time of birth. Activation of kallikrein by neonatal granulocytes was dependent on cell concentration and required oxygen tensions comparable to those in the neonate but above the range in the fetus. Granulocytes of the neonate, unlike those of adult subjects, lacked kininase activity.Thus, bradykinin can constrict and dilate vessels as required for the transition of fetal to neonatal circulation. Bradykinin can be produced in plasma of the newborn by decreases in temperature, such as occur in the umbilical blood at birth, and by exposure to granulocytes which are present in the circulation in increased numbers shortly after birth. We propose that bradykinin is produced at birth and may be a mediator of neonatal circulatory changes.
在氧分压高于40 mmHg(与新生儿的氧分压相当)的体外环境中,缓激肽是人类脐动脉、脐静脉以及羔羊动脉导管的强效收缩剂。缓激肽还能够使羔羊的肺血管产生显著扩张。从理论上讲,激肽能够引发新生儿所需的一些快速循环变化。本研究旨在探讨激肽作为此类变化介质的作用。56名新生儿出生时脐带血中的缓激肽浓度显著高于成年受试者的血液水平(分别为12.8±4.3 ng/ml和2.0 ng/ml或更低)。脐动脉血中含有无活性的激肽前体(激肽原)和无活性的激肽释放酶(激肽释放酶)。通过暴露于新生儿粒细胞或使脐带血温度从37℃降至27℃,血浆激肽释放酶被激活,随后激肽形成且激肽原减少。出生时脐动脉血温度会出现类似程度的下降。新生儿粒细胞对激肽释放酶的激活取决于细胞浓度,且需要与新生儿相当但高于胎儿范围内的氧分压。与成年受试者的粒细胞不同,新生儿的粒细胞缺乏激肽酶活性。因此,缓激肽能够根据胎儿向新生儿循环转变的需要收缩和扩张血管。缓激肽可通过温度降低(如出生时脐血中发生的情况)以及暴露于出生后不久循环中数量增加的粒细胞而在新生儿血浆中产生。我们认为缓激肽在出生时产生,可能是新生儿循环变化的介质。